AlloVir to merge with Kalaris Therapeutics
Click Here to Manage Email Alerts
AlloVir, an allogeneic T cell immunotherapy company, will merge with Kalaris Therapeutics to focus on retinal diseases, according to a press release.
The merger is expected to close in the first quarter of 2025, with the combined company estimated to have about $100 million in cash to operate into the fourth quarter of 2026. The company, which will operate as Kalaris Therapeutics, will focus on the development of TH103 for the treatment of retinal diseases, according to the release. The investigational therapy is being evaluated in a phase 1 clinical trial for the treatment of neovascular age-related macular degeneration.
“We believe that TH103 has the potential to be a meaningful advance for patients suffering from a number of neovascular and exudative retinal diseases,” Andrew Oxtoby, CEO of Kalaris, said in the release. “Kalaris is currently enrolling a phase 1 clinical trial, and we look forward to reporting initial data in treatment-naive nAMD patients in the third quarter of 2025.”
“AlloVir ran a thorough and strategic process, and we believe that this transaction represents the company’s commitment to delivering value to the AlloVir stockholders,” Diana Brainard, CEO of AlloVir, said in the release. “Kalaris is strongly positioned with an innovative clinical stage asset with the potential to disrupt the large anti-VEGF market, with near-term, value-inflecting milestones and a well-credentialed management team to lead the combined company.”
Read more about
Click Here to Manage Email Alerts